Podcast
Mary Jessel, PhD, MBA, Senior Vice President, Global Medical Affairs at Telix Pharmaceuticals
Episode 5 of BioByteas by Windsor Bux welcomes Mary Jessel, PhD, MBA, Senior Vice President, Global Medical Affairs at Telix Pharmaceuticals.
Mary Jessel, SVP of Global Medical Affairs at Telix, discusses the potential of precision medicine in oncology and the importance of targeted drug delivery and personalized dosimetry. She shares her background and career moves, emphasizing the importance of finding passion and planning for the future. Mary also provides leadership advice, focusing on strengths and empowering others. She highlights the significance of putting people and culture first in organizations. The conversation explores setbacks and learning from failures, as well as future advancements and trends in radiopharmaceuticals. Finally, Mary discusses the challenges and obstacles in radio pharma development and adoption.
Takeaway
- Precision medicine has the potential to greatly impact oncology by targeting solid tumors and improving patient outcomes.
- Targeted drug delivery and personalized dosimetry are key areas of focus in the field of radiopharmaceuticals.
- Finding passion and planning for the future are essential for career success.
- Leaders should focus on strengths, empower others, and prioritize people and culture in organizations.
You can also listen to this podcast on Spotifty:
Welcome to BioBytes – Windsor Bux, where we bring you exclusive interviews with the movers and shakers of the biotech and pharmaceutical industry. Join us as we delve into the experiences and valuable insights of leading executives, exploring how they’re shaping the future and making a difference. Get ready for compelling conversations that will expand your knowledge and inspire your own journey in this exciting field!
- Shehnaaz Suliman, M.D, CEO at ReCode Therapeutics
- Sandy Milligan, MD JD, C-Suite Executive & Board Member
- Alex Oshmyansky, MD, PhD, CEO / Co-Founder
- Derek Adams, CEO & President
- Jason Cole – CEO & Chair of the Board, SalioGen
- David Donabedian, PhD – Executive Partner, Interim NewCo CEO, Longwood Fund
- Stephanie Oestreich, PhD, MPA Managing Director at Myeloma Investment Fund
- Ronan O’Hagan, Chief Executive Officer
- Alison Schecter, MD, CMO/CEO
- Joe Foster – Reebok, Founder